The novel arylamidine T-2307 demonstrates in vitro and in vivo Activity against Candida auris

Nathan P. Wiederhold; Laura K. Najvar; Rosie Jaramillo; Marcos Olivo; Hoja Patterson; April Connell; Yoshiko Fukuda; Junichi Mitsuyama; Gabriel Catano; Thomas F. Patterson

doi:10.1128/AAC.02198-19

The novel arylamidine T-2307 demonstrates in vitro and in vivo Activity against Candida auris

Nathan P. Wiederhold, Laura K. Najvar, Rosie Jaramillo, Marcos Olivo, Hoja Patterson, April Connell, Yoshiko Fukuda, Junichi Mitsuyama, Gabriel Catano, Thomas F. Patterson

Producción científica: Article › revisión exhaustiva

36 Citas (Scopus)

Resumen

The in vitro and in vivo activity of the arylamidine T-2307 against Candida auris was evaluated. T-2307 demonstrated in vitro activity (MIC ranges ≤ 0.008 to 0.015 μg/ml at 50% inhibition; 0.125 to >4 μg/ml at 100% inhibition). Treatment with T-2307 (3 mg/kg subcutaneous [SC] once daily) also significantly improved survival (70% at 21 days postinfection) and reduced kidney fungal burden (5.06 log₁₀ CFU/g) compared to control (0% survival and 7.09 log₁₀ CFU/g) (P < 0.01).

Idioma original	English (US)
Número de artículo	e02198
Publicación	Antimicrobial agents and chemotherapy
Volumen	64
N.º	3
DOI	https://doi.org/10.1128/AAC.02198-19
Estado	Published - 2020

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology

Acceder al documento

10.1128/AAC.02198-19

Otros archivos y enlaces

Link to publication in Scopus

Citar esto

@article{2c87a22771e54f75841ce85508ff6a27,

title = "The novel arylamidine T-2307 demonstrates in vitro and in vivo Activity against Candida auris",

abstract = "The in vitro and in vivo activity of the arylamidine T-2307 against Candida auris was evaluated. T-2307 demonstrated in vitro activity (MIC ranges ≤ 0.008 to 0.015 μg/ml at 50% inhibition; 0.125 to >4 μg/ml at 100% inhibition). Treatment with T-2307 (3 mg/kg subcutaneous [SC] once daily) also significantly improved survival (70% at 21 days postinfection) and reduced kidney fungal burden (5.06 log10 CFU/g) compared to control (0% survival and 7.09 log10 CFU/g) (P < 0.01).",

keywords = "Candida auris, Caspofungin, Fluconazole, In vitro susceptibility, Invasive candidiasis, Murine model, T-2307",

author = "Wiederhold, {Nathan P.} and Najvar, {Laura K.} and Rosie Jaramillo and Marcos Olivo and Hoja Patterson and April Connell and Yoshiko Fukuda and Junichi Mitsuyama and Gabriel Catano and Patterson, {Thomas F.}",

year = "2020",

doi = "10.1128/AAC.02198-19",

language = "English (US)",

volume = "64",

journal = "Antimicrobial agents and chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "3",

}

TY - JOUR

T1 - The novel arylamidine T-2307 demonstrates in vitro and in vivo Activity against Candida auris

AU - Wiederhold, Nathan P.

AU - Najvar, Laura K.

AU - Jaramillo, Rosie

AU - Olivo, Marcos

AU - Patterson, Hoja

AU - Connell, April

AU - Fukuda, Yoshiko

AU - Mitsuyama, Junichi

AU - Catano, Gabriel

AU - Patterson, Thomas F.

PY - 2020

Y1 - 2020

N2 - The in vitro and in vivo activity of the arylamidine T-2307 against Candida auris was evaluated. T-2307 demonstrated in vitro activity (MIC ranges ≤ 0.008 to 0.015 μg/ml at 50% inhibition; 0.125 to >4 μg/ml at 100% inhibition). Treatment with T-2307 (3 mg/kg subcutaneous [SC] once daily) also significantly improved survival (70% at 21 days postinfection) and reduced kidney fungal burden (5.06 log10 CFU/g) compared to control (0% survival and 7.09 log10 CFU/g) (P < 0.01).

AB - The in vitro and in vivo activity of the arylamidine T-2307 against Candida auris was evaluated. T-2307 demonstrated in vitro activity (MIC ranges ≤ 0.008 to 0.015 μg/ml at 50% inhibition; 0.125 to >4 μg/ml at 100% inhibition). Treatment with T-2307 (3 mg/kg subcutaneous [SC] once daily) also significantly improved survival (70% at 21 days postinfection) and reduced kidney fungal burden (5.06 log10 CFU/g) compared to control (0% survival and 7.09 log10 CFU/g) (P < 0.01).

KW - Candida auris

KW - Caspofungin

KW - Fluconazole

KW - In vitro susceptibility

KW - Invasive candidiasis

KW - Murine model

KW - T-2307

UR - http://www.scopus.com/inward/record.url?scp=85079886634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85079886634&partnerID=8YFLogxK

U2 - 10.1128/AAC.02198-19

DO - 10.1128/AAC.02198-19

M3 - Article

C2 - 31844006

AN - SCOPUS:85079886634

SN - 0066-4804

VL - 64

JO - Antimicrobial agents and chemotherapy

JF - Antimicrobial agents and chemotherapy

IS - 3

M1 - e02198

ER -

The novel arylamidine T-2307 demonstrates in vitro and in vivo Activity against Candida auris

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto